Investor relations

Developing best-in-class therapies that offer life-changing benefits for cancer patients

Autolus is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

Corporate presentation

Developing Next Generation Programmed T Cell Therapies
January 2022

Download presentation pdf (1.70Mb)

Events

Our team regularly attends key industry conferences to meet with investors and potential partners. Our scientists also represent Autolus at key scientific and medical congresses.

Find out more

Corporate governance

The Board of Directors of Autolus Therapeutics plc sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance.

Find out more